Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Savara Inc. (SVRA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases, and its filings offer detailed insight into the development and financing of its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Through this page, readers can review current and historical reports such as Forms 8-K, which describe material events including public offerings of common stock and pre-funded warrants, royalty funding agreements tied to potential future U.S. net sales of MOLBREEVI, and updates to corporate presentations. Filings also confirm that Savara’s common stock trades on The Nasdaq Global Select Market under the symbol SVRA and describe the company’s status as a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Key documents for investors include periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain information on research and development expenses, general and administrative costs, and other financial data related to the MOLBREEVI program and corporate operations. Current reports on Form 8-K highlight transactions such as underwritten public offerings, the entry into material definitive agreements, and royalty funding arrangements.
Stock Titan enhances these filings with AI-powered summaries that help explain the significance of complex disclosures, including capital-raising transactions, royalty structures, and covenants described in agreements. Users can quickly understand how specific filings relate to Savara’s rare respiratory disease focus, its Phase 3 development of MOLBREEVI, and its preparation for potential commercialization, while still having direct access to the full text of each SEC document.
Savara Inc director and chief executive officer Matthew Pauls reported two changes in his common stock holdings. On 12/14/2025, 195,705 shares of common stock were disposed of at $6.92 per share, representing shares withheld by the company to cover tax liabilities arising from the vesting of previously awarded restricted stock units. After this, he held 1,317,045 shares.
On 12/16/2025, he reported a disposition of 128,995 common shares at a price of $0.00, reflecting a transfer to the GP 2024 Trust, U/A dated 12/20/2024, for no consideration. He is not a trustee of the trust and does not retain investment or voting control over those shares, and disclaims beneficial ownership except to the extent of any pecuniary interest. Following this gift, he beneficially owns 1,188,050 Savara common shares directly.
Savara Inc reported an insider equity transaction by its Chief Operating Officer, Robert Lutz. On 12/14/2025, the company withheld 67,760 shares of Savara common stock at $6.92 per share to cover his tax obligations arising from the vesting of previously awarded restricted stock units.
After this tax-related share withholding, Robert Lutz directly beneficially owned 293,977 shares of Savara common stock.
Savara Inc's chief legal officer reported an equity transaction involving company stock. On 12/14/2025, Savara withheld 39,350 shares of common stock at $6.92 per share to satisfy the reporting person's tax liability arising from the vesting of previously awarded restricted stock units. After this tax withholding transaction, the officer beneficially owned 519,232 shares of Savara common stock directly.
Savara Inc chief business officer Anne Erickson reported a tax-related disposition of common stock. On 12/14/2025, 62,960 shares of Savara common stock were withheld by the company at a price of $6.92 per share to satisfy her tax liability upon vesting of previously awarded restricted stock units. After this withholding transaction, she directly beneficially owns 371,712 Savara shares.
Savara Inc. director Richard Hawkins reported an equity award of 40,000 restricted stock units (RSUs) of Savara common stock dated December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues his service with the company, and each RSU represents a right to receive one share of common stock. He has elected to defer delivery of the vested shares until after his service with Savara ends. Following this grant, he beneficially owns 161,326 shares of Savara common stock in direct ownership.
Savara Inc director David Ramsay reported the acquisition of 40,000 restricted stock units (RSUs) tied to the company’s common stock on December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues to serve with Savara, and each RSU represents a contingent right to receive one share of common stock. The transaction price was listed as $0.00, indicating no cash was paid for the award. Following this grant, Ramsay beneficially owns 2,553,642 shares of Savara common stock in direct ownership.
Savara Inc director Joseph S. McCracken reported acquiring 40,000 shares of common stock on December 9, 2025 at a reported price of $0.00 per share. Following this equity award, he beneficially owns 300,837 shares of Savara common stock directly.
The 40,000 shares are described as restricted stock units (RSUs) that vest in full on December 9, 2026, if he continues his service with the company. Each RSU represents a contingent right to receive one share of common stock, and he has elected to defer receipt of these shares so that they will be delivered after his service with Savara ends.
Savara Inc. (SVRA) director reports stock option exercise. A Savara director filed a Form 4 reporting the exercise of a stock option for 5,860 shares of common stock on 11/14/2025 at an exercise price of $1.46 per share. After this transaction, the director directly holds 121,326 shares of Savara common stock. The related stock option, which vested in twelve equal quarterly installments beginning on March 15, 2016, has now been fully exercised, leaving 0 derivative securities beneficially owned.
Savara Inc. (SVRA) launched a primary offering of 23,809,524 shares of common stock and pre-funded warrants to purchase 7,142,857 shares. The shares are priced at $4.20 and the pre-funded warrants at $4.199 with a $0.001 exercise price. Gross proceeds are $129,992,857, with underwriting discounts of $7,800,000, for net proceeds before expenses of $122,192,857. The company estimates net proceeds of about $121.7 million after expenses.
The underwriters have a 30‑day option to buy up to 4,642,857 additional shares; if fully exercised, net proceeds before expenses would be $140,522,857. Savara plans to use the funds for working capital and general corporate purposes, including advancing MOLBREEVI toward regulatory approval, building commercialization infrastructure and supply, and launch preparation in the U.S. and EU.
The company also disclosed a purchase and sale agreement with RTW Investments under which Savara would receive $75.0 million upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered royalties on U.S. net sales, capped at $187.5 million.
Savara Inc. announced an underwritten offering, agreeing to issue and sell 23,809,524 shares of common stock at $4.20 per share and pre-funded warrants to purchase 7,142,857 shares with a $0.001 exercise price, priced at $4.199 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 4,642,857 shares at the public offering price, less underwriting discounts and commissions.
The transaction was conducted under Savara’s effective Form S-3 shelf, with closing expected on October 31, 2025, subject to customary conditions. Jefferies LLC and Piper Sandler & Co. acted as representatives of the several underwriters. Legal opinions related to the issuance were provided by Polsinelli PC.